Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antipsychotic medication and cognitive function in schizophrenia.

Hiroaki Hori1, Hiroko Noguchi, Ryota Hashimoto

  • 1Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Ogawahigashi, Kodaira, Tokyo, Japan. balius26@hotmail.com

Schizophrenia Research
|June 24, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of autoantibodies against L1CAM in patients with schizophrenia.

Brain, behavior, & immunity - health·2026
Same author

Histiocytic sarcoma with a common clonal origin emerged after 33 years from B-cell precursor acute lymphoblastic leukemia.

Journal of clinical and experimental hematopathology : JCEH·2026
Same author

Ethanolamine as a potential biomarker and therapeutic target for depressive disorder.

Molecular psychiatry·2026
Same author

Safety and Tolerability of Nintedanib in Japanese Patients with Progressive Fibrosing Interstitial Lung Diseases: Final Results of 2-Year Post-Marketing Surveillance.

Advances in therapy·2026
Same author

The effectiveness and neurobiological actions of memory bias modification: a randomized controlled trial.

Psychological medicine·2025
Same author

Neurobiological effects of childhood maltreatment: Health consequences, recovery pathways and clinical implications for holistic care.

Advances in clinical and experimental medicine : official organ Wroclaw Medical University·2025

Non-standard antipsychotic use, including polypharmacy or high doses, is linked to poorer cognitive function in schizophrenia patients. Atypical antipsychotics showed better cognitive outcomes than conventional ones.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Antipsychotic polypharmacy and excessive dosing are common in schizophrenia treatment globally.
  • The impact of non-standard antipsychotic use on cognitive function remains underexplored.

Purpose of the Study:

  • To investigate the association between non-standard antipsychotic use and cognitive function in schizophrenia.
  • To compare cognitive performance between patients on atypical versus conventional antipsychotics.

Main Methods:

  • Assessed neurocognitive functions in 67 chronic schizophrenia patients and 92 controls using WMS-R, WAIS-R, WCST, and ATMT.
  • Defined non-standard use as polypharmacy or dosage >1,000 mg/day chlorpromazine equivalents.
  • Compared cognitive performance based on standard vs. non-standard and atypical vs. conventional antipsychotic use.

Related Experiment Videos

Main Results:

  • Schizophrenia patients performed significantly worse than controls on all cognitive tests.
  • Non-standard antipsychotic use was associated with poorer visual memory, delayed recall, performance IQ, and executive function.
  • Atypical antipsychotics were linked to better visual memory, delayed recall, and executive function compared to conventional antipsychotics.

Conclusions:

  • Evidence suggests an association between antipsychotic medication patterns and cognitive function in schizophrenia.
  • This association may stem from differential illness severity or direct effects of polypharmacy/excessive dosing.
  • Further research is needed to clarify the causal relationship.